Cancer Treatment is majorly constituted by Immunotherapy in improving the prognosis of many patients with a wide variety of haematological and solid malignancies which are driven by the two main key agents known as checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells.
- Track 1-1 Combination with immunomodulatory drugs
- Track 2-2 New Tumour entities
- Track 3-3 Tissue Biomarkers
- Track 4-4 Inflammatory gene signatures